Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis

Journal of Microbiology, Immunology and Infection

Volumn 46, Issue 1, 2013, Pages 65-67

  Lin, Ko Ming ^a,b   Lin, Jing Chi ^a,b   Tseng, Wen Yi ^a   Cheng, Tien Tsai ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Hepatitis C virus; Rheumatoid arthritis; Rituximab

Indexed keywords

AZATHIOPRINE; CELECOXIB; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ANAMNESIS; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; HEPATITIS C; HUMAN; LIVER DISEASE; LIVER FUNCTION TEST; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ARTHRITIS, RHEUMATOID; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; VIRUS ACTIVATION;

EID: 84872606787     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.12.020     Document Type: Article

References (10)

1. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
2. Tsutsumi Y., Kanamori H., Mori A., Tanaka J., Asaka M., Imamura M., et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005, 4:599-608.
3. Suzan F., Ammor M., Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001, 345:1000.
4. Ennishi D., Terui Y., Yokoyama M., Mishima Y., Takahashi S., Takeuchi K., et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008, 83:59-62.
5. Ennishi D., Maeda Y., Niitsu N., Kojima M., Izutsu K., Takizawa J., et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010, 116:5119-5125.
6. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
7. Roccatello D., Baldovino S., Rossi D., Giachino O., Mansouri M., Naretto C., et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008, 34:111-117.
8. Pietrogrande M., De Vita S., Zignego A.L., Pioltelli P., Sansonno D., Sollima S., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011, 10:444-454.
9. Aksoy S., Abali H., Kilickap S., Erman M., Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006, 28:211-214.
10. Cerny A., Chisari V.F. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999, 30:595-601.